文献速递皮肤肿瘤

对 American Joint Committee on Cancer IIB、IIC 和 III 期恶性黑色素瘤患者强化随访影像策略的成本效果分析

Cost-effectiveness analysis of imaging strategy for an intensive follow-up of patients with American Joint Committee on Cancer stage IIB, IIC and III malignant melanoma.
PubMed 文献 · Br J Dermatol · 2018-09-19

这项前瞻性单中心队列研究纳入 290 例 AJCC IIB、IIC 和 III 期黑色素瘤患者,每 6 个月行体部 CT 和脑 MRI,随访 5 年或发现转移即退出。共发现 76 处转移(26.2%);CT 在最初 4 年具成本效果,脑 MRI 仅在最初 1 年具成本效果。

要点

  • 每 6 个月体部 CT 在随访最初 4 年具成本效果。
  • 脑 MRI 仅在随访最初 1 年具成本效果。
  • CT 或 MRI 共发现 76 处转移,占 26.2%。

核心结论

  • 每 6 个月胸部、腹部和盆腔 CT 在 AJCC IIC 和 III 期黑色素瘤患者随访最初 4 年、AJCC IIB 期患者最初 3 年对早期发现转移具成本效果。
  • 脑 MRI 仅在 AJCC IIC 和 III 期黑色素瘤患者随访最初 1 年显示具成本效果。

研究设计与样本

  • 前瞻性单中心队列研究,纳入 290 例临床病理 AJCC IIB、IIC 和 III 期黑色素瘤患者。
  • 患者每 6 个月行体部 CT 和脑 MRI,完成 5 年随访或发现转移后退出研究。
  • 对每项随访影像检查进行成本效果分析。

主要发现

  • 患者共接受 1805 次体部 CT 和 1683 次脑 MRI。
  • CT 或 MRI 共发现 76 处转移(26.2%)。
  • CT 在最初 4 年具成本效果,成本效果比为每例转移患者 4710.70–14437.10 欧元。
  • 脑 MRI 在最初 1 年具成本效果,成本效果比为每例转移患者 14090.60 欧元。

关键数值与推荐

  • CT 成本效果比:每例转移患者 4710.70–14437.10 欧元(最初 4 年)。
  • 脑 MRI 成本效果比:每例转移患者 14090.60 欧元(最初 1 年)。
  • 转移检出:76 处(26.2%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 缺乏生存分析。
  • 缺乏与支付意愿阈值的比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Many follow-up guidelines for patients with high-risk melanoma include expensive imaging studies, serum biomarkers and regular visits to the dermatologist, with little attention to cost-effectiveness. OBJECTIVES: To establish the cost-effectiveness of chest-abdomen-pelvis computed tomography (CT) and brain magnetic resonance imaging (MRI) in a follow-up protocol for patients at high risk of relapse. METHODS: This was a prospective single-centre cohort study of 290 patients with clinicopathological American Joint Committee on Cancer (AJCC) stage IIB, IIC and III melanoma. Patients had a body CT scan and brain MRI every 6 months and were withdrawn from the study after completing a 5-year follow-up or when metastases were detected. A cost-effectiveness analysis for each follow-up radiological procedure was performed. RESULTS: Patients underwent 1805 body CT scans and 1683 brain MRIs. Seventy-six metastases (26·2%) were identified by CT or MRI. CT scan was cost-effective in the first 4 years (cost-effectiveness ratio €4710·70-€14 437·10/patient with metastasis); brain MRI was cost-effective during the first year (cost-effectiveness ratio €14 090·60/patient with metastasis). Limitations included lack of survival analysis and comparisons with willingness-to-pay thresholds. CONCLUSIONS: Six-monthly CT scan of the chest, abdomen and pelvis is a cost-effective technique for the early detection of metastases in the first 4 years of follow-up in patients with AJCC stage IIC and III melanoma, and in the first 3 years in patients with AJCC stage IIB melanoma. In addition, brain MRI has been shown to be cost-effective only in the first year of follow-up in patients with AJCC stage IIC and III melanoma.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Podlipnik S, Moreno-Ramírez D, Carrera C, et al. Cost-effectiveness analysis of imaging strategy for an intensive follow-up of patients with American Joint Committee on Cancer stage IIB, IIC and III malignant melanoma. Br J Dermatol. 2018. PMID: 29876940. doi:10.1111/bjd.16833

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。